Skye Bioscience's CEO Punit Dhillon discusses next generation CB1 inhibition for obesity, and flags how key data from competitor Novo coming this quarter could impact the class

He describes Skye's CB1 program and the rationale for targeting fat tissue, and why today's versions of these therapies could be better and more tolerable than previous generations. Plus, the path forward and how competitor data will be public soon.